Great Lakes Advisors LLC lessened its stake in shares of Glaukos Co. (NYSE:GKOS – Free Report) by 1.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 113,301 shares of the medical instruments supplier’s stock after selling 1,259 shares during the quarter. Great Lakes Advisors LLC’s holdings in Glaukos were worth $16,988,000 as of its most recent SEC filing.
Other hedge funds also recently bought and sold shares of the company. IFP Advisors Inc purchased a new position in Glaukos during the fourth quarter worth about $43,000. Asset Planning Inc purchased a new position in Glaukos during the fourth quarter worth about $90,000. Harvest Fund Management Co. Ltd boosted its stake in Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier’s stock worth $117,000 after buying an additional 860 shares during the period. SBI Securities Co. Ltd. purchased a new position in Glaukos during the fourth quarter worth about $153,000. Finally, Smartleaf Asset Management LLC boosted its stake in Glaukos by 275.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,100 shares of the medical instruments supplier’s stock worth $164,000 after buying an additional 807 shares during the period. Hedge funds and other institutional investors own 99.04% of the company’s stock.
Insider Activity at Glaukos
In related news, Director Gilbert H. Kliman sold 10,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the completion of the sale, the director now directly owns 32,336 shares of the company’s stock, valued at $4,859,454.08. The trade was a 23.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares of the company’s stock, valued at approximately $10,658,380.18. This trade represents a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,744 shares of company stock valued at $2,504,131 in the last ninety days. Insiders own 6.40% of the company’s stock.
Analyst Ratings Changes
Get Our Latest Stock Report on Glaukos
Glaukos Stock Up 5.5 %
Shares of Glaukos stock opened at $103.13 on Thursday. Glaukos Co. has a 52-week low of $84.08 and a 52-week high of $163.71. The company has a 50 day moving average of $143.84 and a 200 day moving average of $138.41. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $5.83 billion, a P/E ratio of -35.93 and a beta of 0.99.
Glaukos (NYSE:GKOS – Get Free Report) last issued its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The firm had revenue of $105.50 million during the quarter, compared to analysts’ expectations of $100.72 million. As a group, research analysts forecast that Glaukos Co. will post -1.08 EPS for the current fiscal year.
Glaukos Profile
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Stories
- Five stocks we like better than Glaukos
- The Most Important Warren Buffett Stock for Investors: His Own
- Ramaco Resources Pins Hopes on Coal’s Untapped Potential
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
- How to Buy Cheap Stocks Step by Step
- Why Energy Transfer Belongs on Your Watchlist
Want to see what other hedge funds are holding GKOS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Glaukos Co. (NYSE:GKOS – Free Report).
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.